Niagen Bioscience Inc (NAGE) is now in the Undervalued zone, suggesting that its current forward PE ratio of 27.33 is considered Undervalued compared with the five-year average of 58.34. The fair price of Niagen Bioscience Inc (NAGE) is between 5.47 to 13.11 according to relative valuation method. Compared to the current price of 4.99 USD , Niagen Bioscience Inc By Undervalued By 8.82%.

Relative Value

Fair Zone

5.47-13.11

Current Price：4.99

8.82%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Niagen Bioscience Inc (NAGE) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Niagen Bioscience Inc (NAGE) has a current Price-to-Book (P/B) ratio of 7.07. Compared to its 3-year average P/B ratio of 11.42, the current P/B ratio is approximately -38.09% higher. Relative to its 5-year average P/B ratio of 11.42, the current P/B ratio is about -38.09% higher. Niagen Bioscience Inc (NAGE) has a Forward Free Cash Flow (FCF) yield of approximately 4.22%. Compared to its 3-year average FCF yield of 2.91%, the current FCF yield is approximately 45.14% lower. Relative to its 5-year average FCF yield of 2.91%, the current FCF yield is about 45.14% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for NAGE competitors is 101.96, providing a benchmark for relative valuation. Niagen Bioscience Inc Corp (NAGE.O) exhibits a P/S ratio of 3.45, which is -96.62% above the industry average. Given its robust revenue growth of 32.86%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of NAGE increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of NAGE in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is NAGE currently overvalued or undervalued?

What is Niagen Bioscience Inc (NAGE) fair value?

NAGE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Niagen Bioscience Inc (NAGE) is between 5.47 to 13.11 according to relative valuation method.

How does NAGE's valuation metrics compare to the industry average?

The average P/S ratio for NAGE's competitors is 101.96, providing a benchmark for relative valuation. Niagen Bioscience Inc Corp (NAGE) exhibits a P/S ratio of 3.45, which is -96.62% above the industry average. Given its robust revenue growth of 32.86%, this premium appears sustainable.

What is the current P/B ratio for Niagen Bioscience Inc (NAGE) as of Mar 03 2026?

As of Mar 03 2026, Niagen Bioscience Inc (NAGE) has a P/B ratio of 7.07. This indicates that the market values NAGE at 7.07 times its book value.

What is the current FCF Yield for Niagen Bioscience Inc (NAGE) as of Mar 03 2026?

As of Mar 03 2026, Niagen Bioscience Inc (NAGE) has a FCF Yield of 4.22%. This means that for every dollar of Niagen Bioscience Inc's market capitalization, the company generates 4.22 cents in free cash flow.

What is the current Forward P/E ratio for Niagen Bioscience Inc (NAGE) as of Mar 03 2026?

As of Mar 03 2026, Niagen Bioscience Inc (NAGE) has a Forward P/E ratio of 27.33. This means the market is willing to pay $27.33 for every dollar of Niagen Bioscience Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Niagen Bioscience Inc (NAGE) as of Mar 03 2026?

As of Mar 03 2026, Niagen Bioscience Inc (NAGE) has a Forward P/S ratio of 3.45. This means the market is valuing NAGE at $3.45 for every dollar of expected revenue over the next 12 months.

NAGE Valuation